Evidence map›Paper›PMID 40054592›Full record

ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2025

Time-Updated Estimated GFR Variability Is Associated With Mortality, Cardiovascular Disease, and End-Stage Kidney Disease in Patients With CKD: Findings From the CRIC Study.

Hiroki Nishiwaki, Celestin Missikpode, Ana C Ricardo, Wei Yang, Amanda H Anderson, James P Lash, Tanika N Kelly, CRIC Study Investigators

Abstract read
In one paragraph

Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Kidney function and brain health: cognitive and structural signatures across cohorts.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hiroki NishiwakiDepartment of Medicine, University of Illinois-Chicago, Chicago, Illinois; Division of Nephrology, Department of Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan; Showa University Research Administration Center (SURAC), Showa University, Shinagawa, Tokyo, Japan. Electronic address: hnishi4@uic.edu.
Celestin MissikpodeDepartment of Medicine, University of Illinois-Chicago, Chicago, Illinois.
Ana C RicardoDepartment of Medicine, University of Illinois-Chicago, Chicago, Illinois.
Wei YangDivision of Biostatistics, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Amanda H AndersonDepartment of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana.
James P LashDepartment of Medicine, University of Illinois-Chicago, Chicago, Illinois.
Tanika N KellyDepartment of Medicine, University of Illinois-Chicago, Chicago, Illinois.
CRIC Study Investigators

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Scientific and Data Coordinating Center(SDCC) for the P*U01DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI FELDMAN, HAROLD I · 2001 to 2017
$50.1M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
Institutional Clinical and Translational Science AwardUL1TR000003 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2015
$38.9M
Tulane COBRE in Cardiometabolic Diseases Clinical Research CoreP20GM109036 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI Ning Liu · 2016 to 2026
$25.3M
Continuation of the Coordinating Center for the Chronic Renal Insufficiency Cohort (CRIC) StudyU24DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Amanda Hyre Anderson, Laura M Dember · 2018 to 2026
$21.5M
Zonulin Antibodies in Intestinal Permeabilitiy in IDDMM01RR016500 · NCRR · UNIVERSITY OF MARYLAND BALTIMORE · PI ONUKWUGHA, EBERECHUKWU · 2002 to 2009
$20.2M
Study of the Care and Outcomes of REnal InsufficiencyU01DK060902 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI GO, ALAN S · 2001 to 2025
$19.5M
Limited Competition for the Continuation of the Chronic Renal Insufficiency CohorU01DK061021 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI RAHMAN, MAHBOOB · 2001 to 2025
$17.3M
Prospective Renal Insufficiency Cohort Evaluation:PRICEU01DK060984 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI COHEN, DEBBIE L · 2001 to 2025
$17.0M
Prospective Cohort Study of Chronic Renal InsufficiencyU01DK061028 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAO, PANDURANGA S · 2001 to 2025
$16.9M
NCATS NIH HHS UL1 TR000003NCATS NIH HHS UL1 TR000424NCATS NIH HHS UL1 TR000433NCATS NIH HHS UL1 TR000439NCRR NIH HHS M01 RR016500NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1 RR029879NIDDK NIH HHS R01 DK118736NIDDK NIH HHS R01 DK119199NIDDK NIH HHS R01 DK125782NIDDK NIH HHS U01 DK060902NIDDK NIH HHS U01 DK060963NIDDK NIH HHS U01 DK060980NIDDK NIH HHS U01 DK060984NIDDK NIH HHS U01 DK060990NIDDK NIH HHS U01 DK061021NIDDK NIH HHS U01 DK061022NIDDK NIH HHS U01 DK061028NIDDK NIH HHS U24 DK060990NIGMS NIH HHS P20 GM109036
6 · The paper itself

Abstract

RATIONALE &

objectivePrevious reports have identified increased estimated glomerular filtration rate (eGFR) variability, measured during a single ascertainment window, as a risk factor for cardiovascular disease and all-cause mortality. We hypothesized that repeated measures of eGFR variability that are time-updated would exhibit stronger associations with common chronic kidney disease outcomes compared with eGFR variability derived from a single ascertainment window. STUDY

designRetrospective cohort study. SETTING &

participants4,224 participants in the Chronic Renal Insufficiency Cohort Study with an eGFR of 20-70mL/min/1.73m EXPOSURE: Variability of eGFR was defined as the coefficient of variation calculated based on measures at 3 consecutive annual follow-up visits, starting at baseline and time-updated repeatedly in 1-year sliding windows. OUTCOME: Cardiovascular disease, end-stage kidney disease, and death. ANALYTICAL APPROACH: Cox proportional hazards models that included baseline covariates and eGFR variability measured during the first ascertainment window (baseline model) and marginal structural models that included repeated measures of eGFR variability and covariates (time-updated model).

resultsIn the baseline and time-updated multivariable adjusted analyses, each standard deviation increase in eGFR rate variability was associated with a respective 1.04-fold (95% CI, 0.96-1.13) and 3.34-fold (95% CI, 2.33-4.79) increased risk of cardiovascular disease, 1.08-fold (95% CI, 0.99-1.18) and 5.97-fold (95% CI, 3.74-9.52) increased risk of end-stage kidney disease, and 1.15-fold (95% CI, 1.08-1.23) and 1.52-fold (95% CI, 1.19-1.94) increased risk of all-cause mortality. LIMITATIONS: Residual confounding and differences in eGFR intervals from real-world clinical practice.

conclusionsVariability in eGFR over time is independently associated with risks of cardiovascular and kidney outcomes and mortality, even after accounting for the absolute level of eGFR and eGFR slope. PLAIN-LANGUAGE SUMMARY: Estimated glomerular filtration rate (eGFR) is a key indicator of kidney function calculated from routine clinical blood test results. It is well established that variability in eGFR over time is associated with poor patient outcomes such as mortality. However, previous analyses have primarily focused on the relationship between the initial eGFR variability observed and future adverse events. In this study, we continuously updated eGFR variability over time and analyzed its association with the development of cardiovascular disease, end-stage kidney disease, and mortality. Our findings demonstrated a stronger association between time-updated eGFR variability and these outcomes compared with the previous analytical methods.

Indexed as

Cardiovascular DiseasesGlomerular Filtration RateKidney Failure, ChronicRenal Insufficiency, ChronicAgedCohort StudiesFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsTime FactorsCardiovascular diseasechronic kidney diseaseeGFR variabilityend-stage kidney diseasemarginal structure modelmortalitytime-updated

Identifiers

PMID40054592
PMCPMC13143139

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.